1
|
Čerina D, Matkovic V, Katić K, Belac Lovasic I, Separovic R, Canjko I, Bajić Ž, Vrdoljak E. 41P Comprehensive genomic profiling in the management of ovarian cancer: National results from Croatia. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
2
|
Omrcen T, Katic A, Tomic S, Eterovic D, Vrdoljak E. Does metastatic colorectal cancer in elderly patients have specific features: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment? Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
3
|
Vrdoljak J, Boban T, Petrić Miše B, Boraska Jelavić T, Bajić Ž, Tomić S, Vrdoljak E. Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study. Jpn J Clin Oncol 2019; 49:347-353. [PMID: 30796833 DOI: 10.1093/jjco/hyz011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2018] [Revised: 12/21/2018] [Accepted: 01/15/2019] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The optimal first-line therapy of advanced ovarian cancer still remains questionable: standard paclitaxel-carboplatin (TC), dose-dense TC, intraperitoneal chemotherapy or TC plus bevacizumab. In this study, we present the real-life results of dose-dense treatment of the single-institution on Caucasian population. METHODS A retrospective cohort study was used on consecutive samples of 74 patients treated with the conventional 3-weekly TC protocol (2008-11) and on 70 treated with TC dose-dense protocol (2012-16). The primary endpoint of this study was overall survival (OS). Secondary endpoints were progression free-survival (PFS) and toxicity. We made adjustments for age, pathohistological type, tumor grade, stage and postoperative residual disease by Cox regression. RESULTS After adjustment for pre-planned clinical and sociodemographic factors, patients treated with dose-dense protocol showed a significantly lower hazard for dying from any cause, than patients treated with conventional protocol (HR = 0.50; 95% CI 0.26-0.98; P = 0.042). Median OS, at 60 months follow-up had not been reached in the dose-dense group, while in the standard treatment group was 48 months (95% CI 33-62). Unadjusted PFS was significantly longer in the dose-dense group (HR = 0.58; 95% CI 0.38-0.88; P = 0.011), but not after the adjustment (P = 0.096). Generally, the level of toxicity was similar in both groups of patients. The need for blood transfusions and usage of filgrastim was significantly higher in the TC dd group. The incidence of neutropenia and thrombocytopenia Grade 3 or 4 were not significantly different in both regimens. CONCLUSIONS Our retrospective study has shown the superior efficacy and comparable toxicity of dose-dense chemotherapy regimen over the conventional regimen in treatment of ovarian cancer on Caucasian population at a single-institution.
Collapse
Affiliation(s)
- J Vrdoljak
- University of Split, Medical School, Šoltanska 2, 21000 Split, Croatia
| | - T Boban
- Department of Oncology, Clinical Hospital Center Split, Spinčićeva 1, 21000 Split, Croatia
| | - B Petrić Miše
- Department of Oncology, Clinical Hospital Center Split, Spinčićeva 1, 21000 Split, Croatia
| | - T Boraska Jelavić
- Department of Oncology, Clinical Hospital Center Split, Spinčićeva 1, 21000 Split, Croatia
| | - Ž Bajić
- Scientific Unit, Psychiatric Hospital Sveti Ivan, Jankomir 11, 10000 Zagreb, Croatia
| | - S Tomić
- Department of Pathology, Forensic Medicine and Cytology, Clinical Hospital Split, Spinčićeva 1, 21000 Split, Croatia
| | - E Vrdoljak
- Department of Oncology, Clinical Hospital Center Split, Spinčićeva 1, 21000 Split, Croatia
| |
Collapse
|
4
|
Sundov D, Petric Mise B, Mrklic I, Bacic B, Vrdoljak E, Tomic S. Prognostic significance of MAPK, Topo IIα and E-cadherin immunoexpression in ovarian serous carcinomas. Neoplasma 2019; 64:289-298. [PMID: 28052682 DOI: 10.4149/neo_2017_217] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Ovarian cancer accounts for only 3% of all cancers in women but is the most lethal gynaecologic malignancy. Low-grade and high-grade ovarian serous carcinomas (OSCs) represent two different diseases with different prognosis, approaches to detection and treatment. We assessed correlation between, MAPK, topoIIα, E-cadherin immunoexpression and clinicopathological features with overall survival (OS) in OSCs. The study included 81 patients undergoing surgery between January 1995 and December 2005.Formalin fixed paraffin embedded tumour sections were reviewed and examined immunohistochemically using antibodies against MAPK, topoIIα and E-cadherin. The clinicopathological features included: age at surgery, stage according to the criteria of the International Federation of Gynecology and Obstetrics (FIGO), tumour grade, residual disease and vascular invasion. Only ten patients (12.3%) were diagnosed in early FIGO stage of disease. According to morphological criteria, 13.6% of tumor samples were low-grade OSCs and 86.4% were high-grade OSCs. On uninominal analysis, residual disease (p<0.001), E-cadherin (p<0.001), vascular invasion (p=0.002), high-grade morphology (p=0.025) and FIGO stage III-IV (p=0.010) were related to significantly shorter OS. We found no significant association between, MAPK and topoIIα expression and OS. Multinominal analysis revealed that only residual disease (p<0.001) and negative E-cadherin immunoexpression were useful independent predictors of unfavourable clinical outcome and shorter OS.
Collapse
|
5
|
Ban M, Viculin J, Tomic S, Capkun V, Strikic A, Mise BP, Utrobicic I, Vrdoljak E. Retrospective analysis of efficacy of trastuzumab in adjuvant treatment of HER 2 positive early breast cancer - single institution experience. Neoplasma 2019; 63:761-7. [PMID: 27468880 DOI: 10.4149/neo_2016_513] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Addition of trastuzumab to chemotherapy is the cornerstone of adjuvant treatment of early HER2 positive breast cancer. Clinical trials and metaanalyses of adjuvant trastuzumab have shown significant reduction in risk of recurrence and death. Nevertheless, the real magnitude of the effect of any drug must be reevaluated in daily clinical conditions, due to the fact that daily clinical practice often differs from conditions in clinical trials. In order to measure the benefit of adding adjuvant trastuzumab in HER 2 positive early breast cancer treatment, we have performed retrospective analysis in a single institution on consecutive patients divided in 2 cohorts: one, treated in "pre - trastuzumab" and the other in "trastuzumab era". Between 2003 and 2012, 258 consecutive HER 2 positive patients with early breast cancer have been treated with adjuvant chemotherapy, 103 patients did not received trastuzumab (patients treated from 2003 till 2007), and 155 (patients treated from 2008 till 2012) received trastuzumab. Patients who received trastuzumab experienced significantly longer median disease-free survival (107 vs. 92 months, LR: 11.6, p <0.001); breast cancer-specific survival (130 vs. 117 months, LR: 10.7, p < 0.001) and median overall survival (123 vs. 108 months LR = 11.6, p < 0.001). The benefits of adding trastuzumab were independent of chemotherapy regimen and hormonal therapy. This retrospective analysis has shown a clear, statistically significant benefit of adjuvant trastuzumab in treatment of early, HER2 positive breast cancer in daily clinical practice, and confirmed the results of the registration clinical trials.
Collapse
|
6
|
Bošković L, Gašparić M, Petrić Miše B, Petković M, Gugić D, Ban M, Jazvić M, Dabelić N, Belac Lovasić I, Vrdoljak E. Optimisation of breast cancer patients' follow-up - potential way to improve cancer care in transitional countries. Eur J Cancer Care (Engl) 2017; 26. [DOI: 10.1111/ecc.12514] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/08/2016] [Indexed: 11/30/2022]
Affiliation(s)
- L. Bošković
- Clinic for Oncology and Radiotherapy; University Hospital Split; Split Croatia
| | | | - B. Petrić Miše
- Clinic for Oncology and Radiotherapy; University Hospital Split; Split Croatia
| | - M. Petković
- Clinic for Oncology and Radiotherapy; University Hospital Rijeka; Rijeka Croatia
| | - D. Gugić
- University Hospital Osijek; Osijek Croatia
| | - M. Ban
- Clinic for Oncology and Radiotherapy; University Hospital Split; Split Croatia
| | - M. Jazvić
- Department of Oncology and Nuclear Medicine; University Hospital Sestre Milosrdnice; Zagreb Croatia
| | - N. Dabelić
- Department of Oncology and Nuclear Medicine; University Hospital Sestre Milosrdnice; Zagreb Croatia
| | - I. Belac Lovasić
- Clinic for Oncology and Radiotherapy; University Hospital Rijeka; Rijeka Croatia
| | - E. Vrdoljak
- Clinic for Oncology and Radiotherapy; University Hospital Split; Split Croatia
| |
Collapse
|
7
|
Juretic A, Srdelic Mihalj S, Kuzmic-Prusac I, Spagnoli G, Vrdoljak E, Petric-Mise B, Capkun V. A retrospective study of cancer testis antigens MAGE-A1 and MAGE-A4 expression in high grade endometrial cancer. Eur J Cancer 2017. [DOI: 10.1016/s0959-8049(17)30371-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
8
|
Zielinski C, Gligorov J, Marschner N, Puglisi F, Vrdoljak E, Castan JC, de Ducla S, Deurloo R, Easton V, von Minckwitz G. Exploratory analyses of candidate predictive and prognostic tissue biomarkers (BMs) in the open-label randomised phase III TANIA trial of bevacizumab (BEV) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw392.24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
9
|
Pivot X, Poole C, Martín M, Gligorov J, Barrios C, Vrdoljak E, Gianni L, Ten Tije A, Machackova Z, Truman M, Steger G. An open-label, multinational, multicentre, phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients with HER2-positive early or metastatic breast cancer (UmbHER1): Interim safety results from early breast cancer studies. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw364.66] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Ann Oncol 2016; 27:2046-2052. [PMID: 27502725 DOI: 10.1093/annonc/mdw316] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Accepted: 07/28/2016] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND The randomised phase III TANIA trial demonstrated that continuing bevacizumab with second-line chemotherapy for locally recurrent/metastatic breast cancer (LR/mBC) after progression on first-line bevacizumab-containing therapy significantly improved progression-free survival (PFS) compared with chemotherapy alone [hazard ratio (HR) = 0.75, 95% confidence interval (CI) 0.61-0.93]. We report final results from the TANIA trial, including overall survival (OS) and health-related quality of life (HRQoL). PATIENTS AND METHODS Patients with HER2-negative LR/mBC that had progressed on or after first-line bevacizumab plus chemotherapy were randomised to receive standard second-line chemotherapy either alone or with bevacizumab. At second progression, patients initially randomised to bevacizumab continued bevacizumab with their third-line chemotherapy, but those randomised to chemotherapy alone were not allowed to cross over to receive third-line bevacizumab. The primary end point was second-line PFS; secondary end points included third-line PFS, combined second- and third-line PFS, OS, HRQoL and safety. RESULTS Of the 494 patients randomised, 483 received second-line therapy; 234 patients (47% of the randomised population) continued to third-line study treatment. The median duration of follow-up at the final analysis was 32.1 months in the chemotherapy-alone arm and 30.9 months in the bevacizumab plus chemotherapy arm. There was no statistically significant difference between treatment arms in third-line PFS (HR = 0.79, 95% CI 0.59-1.06), combined second- and third-line PFS (HR = 0.85, 95% CI 0.68-1.05) or OS (HR = 0.96, 95% CI 0.76-1.21). Third-line safety results showed increased incidences of proteinuria and hypertension with bevacizumab, consistent with safety results for the second-line treatment phase. No differences in HRQoL were detected. CONCLUSIONS In this trial, continuing bevacizumab beyond first and second progression of LR/mBC improved second-line PFS, but no improvement in longer term efficacy was observed. The second-line PFS benefit appears to be achieved without detrimentally affecting quality of life. CLINICALTRIALSGOV NCT01250379.
Collapse
Affiliation(s)
- E Vrdoljak
- Department of Oncology, University Hospital Split, Split, Croatia
| | | | - C Zielinski
- Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria.,Central European Cooperative Oncology Group (CECOG)
| | - J Gligorov
- Assistance Publique Hôpitaux de Paris-Tenon, IUC-UPMC, Sorbonne University, Paris, France
| | - J Cortes
- Ramon y Cajal University Hospital, Madrid.,Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | - F Puglisi
- Department of Medical and Biological Sciences, University of Udine, Udine.,Department of Oncology, University Hospital of Udine, Udine, Italy
| | - M Aapro
- Multidisciplinary Institute of Oncology, Clinique de Genolier, Genolier, Switzerland
| | - L Fallowfield
- Sussex Health Outcomes Research and Education in Cancer (SHORE-C), Brighton and Sussex Medical School, University of Sussex, Falmer, UK
| | - A Fontana
- Medical Oncology Unit 2, Pisa Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy
| | - M Inbar
- Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
| | - Z Kahan
- Department of Oncotherapy, University of Szeged, Szeged, Hungary
| | - A Welt
- West German Cancer Center, University Duisburg-Essen, Essen.,German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany
| | - C Lévy
- Oncology Department, Centre François Baclesse, Caen
| | - E Brain
- Institut Curie-Hôpital René Huguenin, Saint-Cloud
| | - X Pivot
- Oncology Department, Jean Minjoz University Hospital, Besançon, France
| | - C Putzu
- Oncology Unit, University Hospital of Sassari, Sassari, Italy
| | | | | | - V Easton
- Stamford Consultants AG, on behalf of F Hoffmann-La Roche Ltd, Basel, Switzerland
| | | |
Collapse
|
11
|
Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, Gonzalez-Martin A, Ebel K, Easton V, von Minckwitz G. Abstract P6-14-01: Final results of the TANIA randomized phase III trial of bevacizumab (BEV) after progression on 1st-line BEV therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-14-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: The open-label randomized phase III TANIA trial (NCT01250379) evaluated 2nd-line BEV-containing therapy in BEV-pretreated LR/mBC. The primary objective was met: 2nd-line PFS was statistically significantly improved in patients (pts) receiving further BEV (hazard ratio [HR] 0.75, 95% CI 0.61–0.93; p=0.0068) [von Minckwitz, Lancet Oncol 2014]. We report final efficacy, safety, and health-related quality of life (HRQoL) results.
METHODS: Eligible pts had HER2-negative LR/mBC that had progressed on/after 1st-line BEV plus chemotherapy (CT). Pts were randomized to receive 2nd-line CT (investigator's choice) either alone or combined with BEV (15 mg/kg q3w or 10 mg/kg q2w) until disease progression (PD), unacceptable toxicity, or consent withdrawal. At 2nd PD, pts in the CT arm received 3rd-line CT without BEV (no crossover); pts initially randomized to BEV–CT received 3rd-line BEV–CT. Secondary endpoints included 3rd-line PFS, 2nd- and 3rd-line PFS (from randomization to 3rd PD/death), overall survival (OS), HRQoL, and safety. HRQoL was assessed using FACT-B at baseline, every 8/9 weeks (depending on treatment schedule) during 2nd-line therapy, and at the time of 2nd PD. Prespecified HRQoL analyses included differences between treatment arms in mean change from baseline for each FACT-B subscale.
RESULTS: At the time of data cut-off for the prespecified final analysis (April 30, 2015, 24 months after the last pt was randomized), median follow-up was 32.1 vs 30.9 months in the CT vs BEV–CT arms, respectively. All pts had stopped study treatment. Of the 494 pts randomized to 2nd-line therapy, 234 began 3rd-line therapy (105 initially randomized to CT; 129 from the BEV–CT arm, of whom 17 received CT without BEV). The most commonly selected 3rd-line CT was vinorelbine (33% of CT pts vs 31% of BEV–CT pts).
EndpointNo. of events/pts (%)Median, months (95% CI)Stratified HR (95% CI)p-value CTBEV–CTCTBEV–CT 3rd-line PFS99/105 (94)124/129 (96)2.9 (2.2-3.9)3.8 (2.4-5.1)0.79 (0.59-1.06)0.10802nd- and 3rd-line PFS177/247 (72)206/247 (83)10.7 (9.2-12.5)12.8 (10.7-14.5)0.85 (0.68-1.05)0.1349OS156/247 (63)163/247 (66)18.7 (15.4-21.2)19.7 (17.6-21.0)0.96 (0.76-1.21)0.7253
Subgroup analyses of 3rd-line PFS and OS according to stratification factors were consistent with the overall ITT result. Before study closure, 68% and 61% of pts in the 3rd-line ITT population CT and BEV–CT arms, respectively, received further CT. 3rd-line safety results showed no new safety signals. At week 8/9, mean change from baseline for all FACT-B subscales was <1.5 points in either direction in both treatment arms, representing no significant difference. Similarly, exploratory HRQoL analyses of the physical and functional wellbeing subscales using mixed-model repeated measures and responder analyses revealed no meaningful significant differences between treatment arms.
CONCLUSIONS: Although BEV given after PD on 1st-line BEV-containing therapy showed improvement in 2nd-line PFS, no OS benefit was demonstrated. No new safety signals were observed. There were no differences in HRQoL between treatment arms, suggesting that the PFS benefit with BEV is achieved with maintained HRQoL.
Citation Format: Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, Gonzalez-Martin A, Ebel K, Easton V, von Minckwitz G. Final results of the TANIA randomized phase III trial of bevacizumab (BEV) after progression on 1st-line BEV therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-14-01.
Collapse
Affiliation(s)
- E Vrdoljak
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| | - N Marschner
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| | - C Zielinski
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| | - J Gligorov
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| | - J Cortes
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| | - F Puglisi
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| | - M Aapro
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| | - L Fallowfield
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| | - A Fontana
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| | - M Inbar
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| | - Z Kahan
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| | - A Welt
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| | - C Lévy
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| | - E Brain
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| | - X Pivot
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| | - C Putzu
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| | - A Gonzalez-Martin
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| | - K Ebel
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| | - V Easton
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| | - G von Minckwitz
- Center of Oncology, Split, Croatia; Outpatient Cancer Center, Freiburg, Germany; Comprehensive Cancer Center, Medical University Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Hôpital Tenon, Paris, France; Vall d'Hebron University Hospital, Barcelona, Spain; University Hospital of Udine, Udine, Italy; Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland; Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, United Kingdom; University Hospital of Pisa, Istituto Toscana Tumori, Pisa, Italy; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; University of Szeged, Szeged, Hungary; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Centre François Baclesse, Caen, France; Institut Curie – Hôpital René Huguenin, Saint-Cloud, France; University Hospital Jean Minjoz, Besançon, France; University Hospital of Sassari, Sassari, Italy
| |
Collapse
|
12
|
Vrdoljak E, Torday L, Szczylik C, Kharkevich G, Bavbek S, Sella A. Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe. Expert Opin Pharmacother 2015; 17:93-104. [PMID: 26619144 DOI: 10.1517/14656566.2016.1107043] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
INTRODUCTION The incidence and mortality rates of kidney cancer in the Central and Eastern European (CEE) region are among the highest in the world. Access to second and subsequent lines of metastatic renal cell carcinoma (mRCC) therapies is highly varied in the region. Despite the increasing body of evidence supporting the clinical benefit of multiple lines of treatment, access to treatment beyond first line is restricted in many of these countries. AREAS COVERED The adoption of targeted therapies for the first-line treatment of mRCC in the region was slow and faced many obstacles. In order to evaluate the current status of treatment beyond the first-line setting in the CEE region, this review examines the availability and reimbursement of mRCC drugs and clinical practice in institutions that treat patients with mRCC. EXPERT OPINION This review highlights the need to raise awareness among physicians, payers and regulators on clinical trial and cost-effectiveness data regarding the treatment of mRCC beyond the first line. The obstacles to mRCC drug access highlighted in this review need to be overcome to ensure that patients are receiving the best treatment available.
Collapse
Affiliation(s)
- E Vrdoljak
- a University Hospital Split , Department of Oncology , Split , Croatia
| | - L Torday
- b University of Szeged , Department of Oncotherapy , Szeged , Hungary
| | - C Szczylik
- c Central Clinical Hospital , Department of Oncology, Military Institute of Medicine , Warsaw , Poland
| | - G Kharkevich
- d NN Blokhin Russian Cancer Research Center , Biotherapy Department , Moscow , Russia
| | - S Bavbek
- e VKV American Hospital , Div. Medical Oncology , Istanbul , Turkey
| | - A Sella
- f Assaf Harofeh Centre Zerifin, Department of Oncology , Sackler School of Medicine, Tel Aviv University , Tel Aviv , Israel
| |
Collapse
|
13
|
Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Hawkins RE, Crinò L, Kim TM, Carteni G, Eberhardt WEE, Zhang K, Fly K, Matczak E, Lechuga MJ, Hariharan S, Bukowski R. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer 2015; 113:12-9. [PMID: 26086878 PMCID: PMC4647545 DOI: 10.1038/bjc.2015.196] [Citation(s) in RCA: 139] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2015] [Revised: 04/22/2015] [Accepted: 04/29/2015] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND We report final results with extended follow-up from a global, expanded-access trial that pre-regulatory approval provided sunitinib to metastatic renal cell carcinoma (mRCC) patients, ineligible for registration-directed trials. METHODS Patients ⩾18 years received oral sunitinib 50 mg per day on a 4-weeks-on-2-weeks-off schedule. Safety was assessed regularly. Tumour measurements were scheduled per local practice. RESULTS A total of 4543 patients received sunitinib. Median treatment duration and follow-up were 7.5 and 13.6 months. Objective response rate was 16% (95% confidence interval (CI): 15-17). Median progression-free survival (PFS) and overall survival (OS) were 9.4 months (95% CI: 8.8-10.0) and 18.7 months (95% CI: 17.5-19.5). Median PFS in subgroups of interest: aged ⩾65 years (33%), 10.1 months; Eastern Cooperative Oncology Group performance status ⩾2 (14%), 3.5 months; non-clear cell histology (12%), 6.0 months; and brain metastases (7%), 5.3 months. OS was strongly associated with the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model (n=4065). The most common grade 3/4 treatment-related adverse events were thrombocytopenia (10%), fatigue (9%), and asthenia, neutropenia, and hand-foot syndrome (each 7%). CONCLUSION Final analysis of the sunitinib expanded-access trial provided a good opportunity to evaluate the long-term side effects of a tyrosine kinase inhibitor used worldwide in mRCC. Efficacy and safety findings were consistent with previous results.
Collapse
Affiliation(s)
- M E Gore
- Royal Marsden Hospital NHS Trust, Fulham Road, London SW3 6JJ, UK
| | - C Szczylik
- Military Medical Institute, Department of Oncology, 128 Szaserów Street 04-141 Warsaw, Poland
| | - C Porta
- IRCCS San Matteo University Hospital Foundation, Piazzale C. Golgi, 19, I-27100 Pavia, Italy
| | - S Bracarda
- San Donato Hospital, Istituto Toscano Tumori (ITT), Via Pietro Nenni, 20 52100 Arezzo, Italy
| | - G A Bjarnason
- Sunnybrook Odette Cancer Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5
| | - S Oudard
- Hôpital Européen Georges Pompidou, René Descartes University Paris 5, 20 Rue Leblanc, 75015 Paris, France
| | - S-H Lee
- Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 110-744, South Korea
| | - J Haanen
- The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
| | - D Castellano
- Hospital Universitario 12 de Octubre, Avenida de Córdoba, 28041 Madrid, Spain
| | - E Vrdoljak
- Department of Oncology, Clinical Hospital Center Split, School of Medicine, University of Split, Spinčićeva 1 21000 Split, Croatia
| | - P Schöffski
- University Hospitals Leuven, Leuven Cancer Institute, Catholic University Leuven, Herestraat 49, B-3000 Leuven, Belgium
| | - P Mainwaring
- Mater Adult Hospital, Raymond Terrace, South Brisbane, QLD 4101, Australia
| | - R E Hawkins
- Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
| | - L Crinò
- Azienda Ospedaliera di Perugia, via Dottori, 106156 Perugia, Italy
| | - T M Kim
- Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 110-744, South Korea
| | - G Carteni
- A.O.R.N. 'A Cardarelli', Divisione di Oncologia, via A. Cardarelli, 9-80131 Naples, Italy
| | - W E E Eberhardt
- Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, 45147 Essen, Germany
| | - K Zhang
- Pfizer Oncology, 10555 Science Center Drive, La Jolla, CA 92121, USA
| | - K Fly
- Pfizer Oncology, 558 Eastern Point Road, Groton, CT 06340, USA
| | - E Matczak
- Pfizer Oncology, 235 East 42nd Street, New York, NY 10017, USA
| | - M J Lechuga
- Pfizer Oncology, Pfizer Italia Srl, Via Lorenteggio 257, 20152 Milan, Italy
| | - S Hariharan
- Pfizer Oncology, 235 East 42nd Street, New York, NY 10017, USA
| | - R Bukowski
- Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue/R35, Cleveland, OH 44195, USA
| |
Collapse
|
14
|
von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Láng I, Ciruelos E, De Laurentiis M, Veyret C, De Ducla S, Freudensprung U, Srock S, Gligorov J. Efficacy and Safety in Tania, a Randomised Phase III Trial of Continued or Reintroduced Bevacizumab (Bev) After 1St-Line Bev for Her2-Negative Locally Recurrent/Metastatic Breast Cancer (Lr/Mbc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu329.3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Vrdoljak E, Torday L, Sella A, Leyman S, Bavbek S, Kharkevich G, Mardiak J, Szczylik C, Znaor A, Wilking N. Insights into cancer surveillance in Central and Eastern Europe, Israel and Turkey. Eur J Cancer Care (Engl) 2013; 24:99-110. [PMID: 24661376 DOI: 10.1111/ecc.12149] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/06/2013] [Indexed: 11/28/2022]
Abstract
The current cancer landscape within transitional economies in central and Eastern Europe and the Mediterranean area is not particularly optimistic. Current perceptions are often based on extrapolations from other countries and regions; and hence the authors collaborated with the South Eastern Europe Oncology Group (SEEROG) to collect information on cancer registration in Central and Eastern Europe, Israel and Turkey. Healthcare authorities and specialist oncology centres in 21 countries in the region were contacted for information on cancer registries in their countries. Based on this information, the authors believe that the recording and reporting of data on cancer in the region is at an acceptable level. The authors discuss and compare institution- and population-based registries, and present opinions on elements of an 'ideal registry' based on the survey replies and comparisons with other registries. A comparison with the sources used for GLOBOCAN 2008 illustrates the need for consistent data to be communicated, published and utilised throughout the region and the oncology community. The authors conclude by considering the potential value of collaboration between health authorities across the region, as well as between the clinical and epidemiological communities, to ensure that cancer data are consistently collected, verified and made public.
Collapse
Affiliation(s)
- E Vrdoljak
- Center of Oncology, Clinical Hospital Split, Split, Croatia
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Lindemann K, Christensen RD, Vergote I, Stuart G, Izquierdo MA, Kærn J, Havsteen H, Eisenhauer E, Ridderheim M, Lopez AB, Hirte H, Aavall-Lundquvist E, Vrdoljak E, Green J, Kristensen GB. First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. Ann Oncol 2012; 23:2613-2619. [PMID: 22539562 DOI: 10.1093/annonc/mds060] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The addition of anthracyclines to platinum-based chemotherapy may provide benefit in survival in ovarian cancer patients. We evaluated the effect on survival of adding epirubicin to standard carboplatin and paclitaxel. PATIENTS AND METHODS We carried out a prospectively randomized phase III study comparing carboplatin plus paclitaxel (TC; area under the curve 5 and 175 mg/m(2)) with the same combination and epirubicin (TEC; 75 mg/m(2) i.v.). Between March 1999 and August 2001, 887 patients with epithelial ovarian, tubal or peritoneal cancer International Federation of Gynecology and Obstetrics stages IIB-IV were randomized to receive either TC (442 patients) or TEC (445 patients). RESULTS Median time to progression was 16.4 months in the TEC arm and 16.0 months in the TC arm (hazard ratio 0.99; 95% confidence interval [CI]: 0.9-1.2). Median overall survival time was 42.4 months for the TEC arm and 40.2 for the TC arm (hazard ratio 0.96; 95% CI: 0.8-1.1). Grade 3/4 hematologic toxic effects and most grade 3/4 non-hematologic toxic effects were more frequent in the TEC arm. Accordingly, a quality-of-life analysis showed inferiority of TEC versus TC. CONCLUSION The addition of epirubicin to standard carboplatin and paclitaxel treatment did not improve survival in patients with advanced ovarian, tubal or peritoneal cancer.
Collapse
Affiliation(s)
- K Lindemann
- Department of Gynecological Cancer, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
| | - R D Christensen
- Department of Medical Statistics, University of Southern Denmark, Odense, Denmark
| | - I Vergote
- Department of Obstetrics and Gynecology, University Hospital Leuven, Leuven, Belgium
| | - G Stuart
- Department of Gynecologic Oncology, University of British Columbia, Vancouver, Canada
| | - M A Izquierdo
- Institute of Oncology, Catalán Hospital, Catalania, Spain
| | - J Kærn
- Department of Gynecological Cancer, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
| | - H Havsteen
- Department of Oncology, Herlev University Hospital, Herlev, Denmark
| | - E Eisenhauer
- Department of Oncology, Queen's University, Kingston, Ontario, Canada
| | - M Ridderheim
- Department of Gynecologic Oncology, Lund University Hospital, Lund, Sweden
| | - A B Lopez
- Department of Gynecologic Oncology, Queen Elizabeth Hospital, Gateshead, UK
| | - H Hirte
- Department of Oncology, Division of Medical Oncology, Juravinski Cancer Centre, Hamilton, Ontario, Canada
| | | | - E Vrdoljak
- Department of Oncology, University Hospital, Split, Croatia
| | - J Green
- Department of Oncology, Clatterbridge Hospital, Wirral, UK
| | - G B Kristensen
- Department of Gynecological Cancer, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Department of Gynecological Cancer, Institute for Medical Informatics, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
| |
Collapse
|
17
|
von MG, Cortés J, Gligorov J, Marschner NW, Puglisi F, Vrdoljak E, Duenne AA, Zielinski C. OT3-01-04: TANIA: A Randomized Phase III Trial Evaluating Continued and Reintroduced Bevacizumab (BEV) in Patients Previously Treated with 1st-Line BEV for Locally Recurrent/Metastatic Breast Cancer (LR/mBC). Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-ot3-01-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
BEV has repeatedly demonstrated improvements in progression-free survival (PFS) in randomized phase III trials, providing benefit in the 1st- and 2nd-line settings when combined with chemotherapy versus chemotherapy alone. However, the role of BEV in BEV-pretreated LR/mBC is unclear. The TANIA trial (MO22998) was initiated to address this question.
Trial design: TANIA is an open-label randomized multicenter phase III trial. Eligible patients are aged ≥18 years with HER2−negative LR/mBC that has progressed during or after ≥12 weeks of 1st-line BEV combined with chemotherapy for LR/mBC. Maintenance therapy with BEV and/or endocrine therapy before study enrollment is permitted. Patients who have previously received anti-angiogenic therapy other than BEV in the 1st-line LR/mBC setting are not eligible. BEV-specific exclusion criteria are similar to previous randomized trials (eg inadequately controlled hypertension; history of nephrotic syndrome, hypertensive crisis, gastrointestinal perforation, or grade 3/4 venous thromboembolism; significant vascular disease). All patients must provide written informed consent. After stratification according to hormone receptor status, time to 1st progression (<6 vs ≥6 months), choice of chemotherapy (taxane vs non-taxane vs vinorelbine), and LDH level (≤1.5 vs >1.5 * upper normal limit), eligible patients are randomized 1:1 to 2nd-line treatment with either standard single-agent chemotherapy alone (arm 1) or standard single-agent chemotherapy combined with BEV (15 mg/kg q3w or 10 mg/kg q2w, depending on the chosen chemotherapy regimen; arm 2). 2nd-line therapy is continued until disease progression, unacceptable toxicity, or patient withdrawal. At progression, patients in arm 1 receive 3rd-line chemotherapy without BEV (ie no crossover permitted) and those in arm 2 receive 3rd-line chemotherapy in combination with BEV (unless prevented by unacceptable toxicity). Maintenance endocrine therapy is permitted in both arms (in combination with BEV in arm 2). At 3rd progression, BEV is permitted in all patients. The primary objective is to determine the therapeutic benefit of continued or reintroduced BEV in combination with 2nd-line chemotherapy for patients previously treated with 1st-line BEV plus chemotherapy, determined by the duration of PFS from the time of randomization to 2nd progression (or death). Additional objectives include evaluation of the interval between 2nd and 3rd progression, the interval between randomization and 3rd progression, PFS in stratified subgroups, overall response rate to 2nd-line therapy, overall survival (OS), 1-year OS rate, safety, quality of life (FACT-B and EQ-5D), and translational research. The sample size of 488 patients is calculated assuming median PFS of 7 months in arm 1, a hazard ratio of 0.75, a recruitment period of 30 months, and a 5% dropout rate (ie 439 eligible patients), providing 80% power at two-sided a=0.05. As of 15th June 2011, 23 patients have been enrolled. The primary analysis is planned after 384 patients have shown progression on 2nd-line therapy.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT3-01-04.
Collapse
Affiliation(s)
- Minckwitz G von
- 1German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany; Vall d'Hebron University Hospital, Barcelona, Spain; APHP Tenon-APREC, Paris, France; Outpatient Cancer Centre, Freiburg, Germany; University Hospital of Udine, Udine, Italy; Centre of Oncology, Split, Croatia; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Medical University of Vienna, Vienna, Austria
| | - J Cortés
- 1German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany; Vall d'Hebron University Hospital, Barcelona, Spain; APHP Tenon-APREC, Paris, France; Outpatient Cancer Centre, Freiburg, Germany; University Hospital of Udine, Udine, Italy; Centre of Oncology, Split, Croatia; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Medical University of Vienna, Vienna, Austria
| | - J Gligorov
- 1German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany; Vall d'Hebron University Hospital, Barcelona, Spain; APHP Tenon-APREC, Paris, France; Outpatient Cancer Centre, Freiburg, Germany; University Hospital of Udine, Udine, Italy; Centre of Oncology, Split, Croatia; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Medical University of Vienna, Vienna, Austria
| | - NW Marschner
- 1German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany; Vall d'Hebron University Hospital, Barcelona, Spain; APHP Tenon-APREC, Paris, France; Outpatient Cancer Centre, Freiburg, Germany; University Hospital of Udine, Udine, Italy; Centre of Oncology, Split, Croatia; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Medical University of Vienna, Vienna, Austria
| | - F Puglisi
- 1German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany; Vall d'Hebron University Hospital, Barcelona, Spain; APHP Tenon-APREC, Paris, France; Outpatient Cancer Centre, Freiburg, Germany; University Hospital of Udine, Udine, Italy; Centre of Oncology, Split, Croatia; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Medical University of Vienna, Vienna, Austria
| | - E Vrdoljak
- 1German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany; Vall d'Hebron University Hospital, Barcelona, Spain; APHP Tenon-APREC, Paris, France; Outpatient Cancer Centre, Freiburg, Germany; University Hospital of Udine, Udine, Italy; Centre of Oncology, Split, Croatia; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Medical University of Vienna, Vienna, Austria
| | - A-A Duenne
- 1German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany; Vall d'Hebron University Hospital, Barcelona, Spain; APHP Tenon-APREC, Paris, France; Outpatient Cancer Centre, Freiburg, Germany; University Hospital of Udine, Udine, Italy; Centre of Oncology, Split, Croatia; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Medical University of Vienna, Vienna, Austria
| | - C Zielinski
- 1German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany; Vall d'Hebron University Hospital, Barcelona, Spain; APHP Tenon-APREC, Paris, France; Outpatient Cancer Centre, Freiburg, Germany; University Hospital of Udine, Udine, Italy; Centre of Oncology, Split, Croatia; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Medical University of Vienna, Vienna, Austria
| |
Collapse
|
18
|
Vrdoljak E, Boban M, Omrcen T, Hrepic D, Fridl-Vidas V, Boskovic L. Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer. Neoplasma 2011; 58:172-8. [PMID: 21275468 DOI: 10.4149/neo_2011_02_172] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Optimal first-line chemotherapy for metastatic breast cancer (MBC) is challenging, particularly in patients previously treated with (neo) adjuvant anthracyclines/taxanes. Based on preclinical synergy with mitomycin C (MMC) and capecitabine in human tumor xenografts, we conducted a phase II study of first-line capecitabine and MMC in MBC. Patients received 3-weekly chemotherapy comprising MMC 8 mg/m² day 1 and capecitabine 1000 mg/m² twice daily, days 1-14. Combination chemotherapy was administered for a maximum six cycles, single-agent capecitabine could be continued until progressive disease or unacceptable toxicity. Thirty patients were included, objective response rate was 65.5%. After a median follow-up of 18.5 months, median time to progression was 8.5 months and median overall survival was 29.8 months. The main adverse events were thrombocytopenia, pneumonitis and hemolytic uremic syndrome. Our data suggest that first-line capecitabine and MMC has good antitumor activity in MBC, but is associated with MMC-specific toxicity.
Collapse
Affiliation(s)
- E Vrdoljak
- Department of Oncology, Clinical Hospital Split and University of Split School of Medicine, Spinciceva 1, 21000 Split, Croatia.
| | | | | | | | | | | |
Collapse
|
19
|
Vrdoljak E, Boban M, Ban M. Lapatinib in the treatment of HER-2 overexpressing breast cancer. J BUON 2011; 16:393-399. [PMID: 22006739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Lapatinib is the only clinically available agent for the treatment of patients with human epidermal growth factor receptor-2 (HER-2) positive tumors that have progressed on treatment with trastuzumab, taxanes and anthracyclines. Moreover, when given with letrozole in postmenopausal patients with estrogen receptor (ER) and HER-2 positive disease it induces clinically meaningful benefit. Recently presented neoadjuvant data suggests an important place for the combination of trastuzumab and lapatinib in the therapy of early HER-2 positive breast cancer. This article reviews the current status and future perspectives of lapatinib.
Collapse
Affiliation(s)
- E Vrdoljak
- Center of Oncology, Clinical Hospital Split, Split, Croatia.
| | | | | |
Collapse
|
20
|
Vahdat LT, Vrdoljak E, Gomez H, Li RK, Thomas E, Bosserman LD, Sparano JA, Baselga J, Mukhopadhyay P, Valero V. Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1083] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Abstract
It has been suggested that glial cells and/or their progenitors are the primary target cells for radiation-induced demyelination. Cultures of terminally differentiated oligodendrocytes, immature oligodendrocytes, and O-2A progenitor cells were generated from the cerebral cortex and spinal cord of perinatal rat pups. Irradiation of cultures of terminally differentiated oligodendrocytes resulted in a significant increase in the percentage of apoptotic cells from 15% in control to 30% in irradiated samples, with the maximum increase induced by 10 Gy. This increase in apoptosis could be observed by 1 h after irradiation with the maximum level reached at 3-6 h. Apoptotic cells were not detected before or after irradiation of cultures of O-2A progenitor cells or immature oligodendrocytes. These data suggest that radiation-induced apoptosis of terminally differentiated oligodendrocytes may be involved in early demyelination.
Collapse
Affiliation(s)
- E Vrdoljak
- University of Texas M. D. Anderson Cancer Center, Houston
| | | | | | | | | | | |
Collapse
|
22
|
Vrdoljak E, Omrcen T, Hrabar A. Phase II study of bevacizumab in combination with capecitabine as first line treatment in elderly patients with metastatic colorectal cancer (MCC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15074] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15074 Background: The aim of this prospective study was to evaluate efficacy and safety of bevacizumab in combination with capecitabine as first line treatment in elderly patients with MCC. Methods: 40 elderly patients (median age 75 years) with MCC have been treated with bevacizumab in combination with capecitabine as their first line therapy. Regimen consisted of bevacizumab 7.5 mg mg/kg on day 1 plus capecitabine 1000 mg/m2 on day 1–14 followed by 7 days rest. Results: The median follow up time at time of ASCO will be 12 months. Median number of 9 cycles was administrated, ranging from 1 to 23. 3 patients (7.5 %) had complete response, 19 patients (47.5 %) had partial response, 11 patients (27.5 %) had stable disease, 1 patient (2.5 %) progressed according to RECIST criteria and 6 patients (15%) were not evaluated yet. Until this report 15 of 40 patients progressed and 9 of 40 patients died. Median time to progression is 6.37 months. Median overall survival will be reported at ASCO 2009 meeting. The most common hematological adverse events were mild (grade I and II): anemia (27.5%) neutropenia (22.5%), and thrombocytopenia (20%). The most common non-hematological toxicity were mild as well (grade I and II): hand-foot syndrome (70%), arterial hypertension (52.5%), proteinuria (45%), hyperbilirubinemia (45%), diarrhea (25%), loss of appetite (23.5%), fever (22.5%), fatigue (17.5%), tearing (17.5%), and nail changes (12.5%). Grade 3 and 4 adverse events occurred rarely: hand-foot syndrome (12.5%), deep vein thrombosis (7.5%), fever (5%), and arterial hypertension (2.5%). Conclusions: This prospective phase II study has demonstrated that bevacizumab in combination with capecitabine as first line treatment in elderly patients with metastatic colorectal cancer is an effective and well-tolerated regimen. [Table: see text]
Collapse
Affiliation(s)
- E. Vrdoljak
- University Hospital 'split’, Split, Croatia; Roche, Zagreb, Croatia
| | - T. Omrcen
- University Hospital 'split’, Split, Croatia; Roche, Zagreb, Croatia
| | - A. Hrabar
- University Hospital 'split’, Split, Croatia; Roche, Zagreb, Croatia
| |
Collapse
|
23
|
Vrdoljak E, Omrcen T, Boban M, Hrepic D. Capecitabine and mitomycin-C in the therapy of pretreated patients with metastatic colorectal cancer: single center retrospective study with 36 patients. J BUON 2008; 13:513-518. [PMID: 19145672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
PURPOSE To evaluate the therapeutic effectiveness and safety of treatment with capecitabine and mitomycin-C (MMC) in patients with metastatic colorectal cancer previously treated with at least one chemotherapy regimen for recurrent or metastatic disease. PATIENTS AND METHODS A total of 36 patients (male/female 21/15, median age 62.5 years) with metastatic colorectal cancer were treated with capecitabine and MMC as their second, third or fourth line chemotherapy regimen. Chemotherapy consisted of intravenous MMC 6 mg/m(2) on day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1-15 followed by 7-day rest. Treatment courses were repeated every 3 weeks unless there was evidence of progressive disease or unacceptable toxicity. RESULTS All 36 patients were evaluable for toxicity and response. A total of 175 cycles were administered (median 4.86, range 3-6). Two (5.6%) patients achieved complete response, 3 (8.3%) partial response, 14 (38.9%) had stable disease and 16 (44.4%) patients progressed. Median time to tumor progression (TTP) was 4.5 months and median overall survival (OS) 13 months. No toxic deaths occurred. Toxicity was mild and easily manageable. CONCLUSION This retrospective study demonstrated that the combination of capecitabine and MMC is an effective and well-tolerated regimen for patients previously treated for metastatic or recurrent colorectal cancer.
Collapse
Affiliation(s)
- E Vrdoljak
- Center of Oncology, Medical School Split, Clinical Hospital Split, Split, Croatia.
| | | | | | | |
Collapse
|
24
|
Boraska Jelavić T, Barisić M, Drmic Hofman I, Boraska V, Vrdoljak E, Peruzović M, Hozo I, Puljiz Z, Terzić J. Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer. Clin Genet 2006; 70:156-60. [PMID: 16879199 DOI: 10.1111/j.1399-0004.2006.00651.x] [Citation(s) in RCA: 88] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Factors underlying genetic predisposition for development of sporadic colorectal cancer are largely unknown. The fact that this cancer is more common in patients suffering from inflammatory bowel disease raises the question of the relationship between chronic inflammation and cancer. Toll-like receptors 2 (TLR2) and 4 (TLR4) are critical in initiating innate immune response and inflammation toward various bacteria commonly found in the intestine. Recent evidence about the association of polymorphisms in these genes with ulcerative colitis and Crohn's disease, as well as other inflammatory conditions, was the basis for our investigation of their role in sporadic colorectal cancer. We assessed genotype and allele frequencies of TLR2 GT microsatelite polymorphism, TLR2 Arg753Gln, TLR4 Asp299Gly and TLR4 Thr399Ile polymorphisms in 89 colorectal cancer patients and 88 age- and sex-matched controls. The frequency of TLR2 GT microsatelite alleles with 20 and 21 GT repeats was decreased (p = 0.0044 and p = 0.001, respectively), while the frequency of the allele with 31 GT repeats was increased (p = 0.0147) in patients. The mutant allele Asp299Gly of TLR4 gene was slightly more frequent in colorectal cancer patients (p = 0.0269). In conclusion, we report an association of microsatelite GT polymorphisms of TLR2 gene and Asp299Gly polymorphism of the TLR4 gene with sporadic colorectal cancer among Croatians.
Collapse
|
25
|
Grubisić-Cabo F, Vrdoljak E. Drug-induced hepatitis in a patient with malignant melanoma treated with interferon alfa 2b adjuvantly who had been administered gemfibrozil in therapy. Med Oncol 2006; 23:121-4. [PMID: 16645237 DOI: 10.1385/mo:23:1:121] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2004] [Revised: 11/30/1999] [Accepted: 05/18/2005] [Indexed: 11/11/2022]
Abstract
A well-known side effect of chemotherapy, covering a wide range of drugs, is drug-induced hepatitis. We are reporting on a 61-yr-old female patient whose malignant melanoma had been surgically removed, and on whom adjuvant therapy with interferon alfa 2b was initiated. The patient had mild hyperlipidemia, of which she had been aware for several years, but which had gone untreated with medicinal intervention. After the patient was started on interferon alfa therapy, continuously increasing values of triglyceride were measured. Therefore, 3 mo after the introduction of adjuvant therapy, gemfibrozil was prescribed at a dose of 600 mg per day. Within a few days after the patient had been taking this combined therapy, the clinical and laboratory values of drug-induced hepatitis developed. Soon after discontinuance of treatment by both drugs, the signs and symptoms of hepatitis disappeared. Adjuvant interferon therapy was not continued afterward owing to the patient's wish. We do not know if the hepatitis was the side effect to gemfibrozil alone, or the side effect was a result of an interaction between the two drugs. As far as we could find, this is the first case report of possible negative interaction between interferon alfa 2b and gemfibrozil. Our intention in this article is to point out that prescription of any drugs, especially new ones, should be balanced and carefully monitored because of possible side effects.
Collapse
|
26
|
Cufer T, Vrdoljak E. PD-070 SIGN: A Phase II, open-label, randomized study comparinggefitinib (IRESSA) with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80403-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
27
|
Cufer T, Vrdoljak E. Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7035] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- T. Cufer
- Institute of Oncology, Ljubljana, Slovenia; Clin Hosp Split, Split, Croatia
| | - E. Vrdoljak
- Institute of Oncology, Ljubljana, Slovenia; Clin Hosp Split, Split, Croatia
| |
Collapse
|
28
|
Vrdoljak E, Boraska Jelavic T, Saratlija-Novakovic Z, Hamm W. Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in the treatment of locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri. EUR J GYNAECOL ONCOL 2005; 26:602-4. [PMID: 16398217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
The optimal treatment of women with locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri is still undefined. We report a series of four consecutive patients with locally advanced adeno- or adenosquamous carcinomas of the uterine cervix (FIGO Stages IB-IIIB) treated by concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by one to four cycles of consolidation chemotherapy with the same drug combination. After completion of this treatment all patients showed complete clinical remission. Now, after a median follow-up of 40 (range: 13.5-61) months all patients still present with no evidence of disease. Despite the low number of patients in this series we may conclude that concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy with the same drug combination is an efficacious treatment of patients with locally advanced adeno- or adenosquamous carcinomas of the cervix uteri.
Collapse
Affiliation(s)
- E Vrdoljak
- Center of Oncology, Clinical Hospital Split, Croatia
| | | | | | | |
Collapse
|
29
|
Kristensen GB, Vergote I, Stuart G, Del Campo JM, Kaern J, Lopez AB, Eisenhauer E, Aavall-Lundquist E, Ridderheim M, Havsteen H, Mirza MR, Scheistroen M, Vrdoljak E. First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer 2004; 13 Suppl 2:172-7. [PMID: 14656276 DOI: 10.1111/j.1525-1438.2003.13363.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
The objective of this study was to compare the safety and efficacy of carboplatin plus epirubicin and paclitaxel (TEC) to carboplatin and paclitaxel (TC), in the treatment of epithelial ovarian, peritoneal, or tubal carcinoma. Between March 1999 and August 2001, 887 patients were randomized to receive six to nine cycles of paclitaxel (175 mg/m2, 3 h intravenously) followed by carboplatin (AUC 5, Calvert formula) with or without epirubicin (75 mg/m2 intravenously prior to paclitaxel), on a 3-weekly schedule. The primary endpoint was progression-free survival. Demographic information: Residual disease <1 cm was reported on 41% of patients. At the end of treatment, 65% in the TEC and 55% in the TC arm had achieved a clinical complete response, and 18 and 25% a clinical partial response resulting in an overall response rate of 83% in the TEC and 80% in the TC arm, whereas 7 and 9% had progressive disease, respectively. The three-drug combination produced a markedly higher myelotoxicity, resulting in a higher frequency of febrile neutropenia (12.5% of the TEC and 1.5% of the TC patients) and a higher number of dose reductions and treatment delays. Cycle prolongation above seven days was seen in 7 and 5% of cycles in the TEC and TC arm, respectively. Stomatitis > or = grade 3 was also higher with TEC (4% TEC and 0.5% TC). Reductions in left ventricular ejection fraction of more than 15% after six courses were slightly more common with the TEC regimen (3% versus 1.5%), but the difference was not statistically significant (P = 0.2). In conclusion, treatment with the TEC combination produced a higher rate of complete responses than treatment with the TC combination. Toxicity was manageable. Long-term survival data are awaited.
Collapse
Affiliation(s)
- G B Kristensen
- Department of Gynecologic Oncology, The Norwegian Radium Hospital, Oslo, Norway.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Vrdoljak E, Hamm W, Omrcen T, Prskalo T. Long-lasting complete remission of a patient with cervical cancer FIGO IVB treated by concomitant chemobrachyradiotherapy with ifosfamide and cisplatin and consolidation chemotherapy--a case report. EUR J GYNAECOL ONCOL 2004; 25:247-9. [PMID: 15032295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
The treatment of women with already metastasized cervical cancer at initial diagnosis represents a challenge to gynecologic oncologists. We report on a 63-year-old patient with locally advanced squamous cell carcinoma of the cervix uteri with an isolated metastasis to the left ovary. Following treatment with concomitant chemoradiotherapy with ifosfamide and cisplatin and three cycles of consolidation chemotherapy with the same drug combination a complete clinical remission could be documented. At present, 35 months after her disease was diagnosed, she is still without any evidence of disease. The very promising outcome of this patient might suggest that combined chemoradiation which is the standard treatment of locally advanced cervical cancer is justified as well in the metastatic setting, provided the metastatic lesion is covered within the usual radiation field.
Collapse
Affiliation(s)
- E Vrdoljak
- Center of Oncology, Clinical Hospital, Split, Croatia
| | | | | | | |
Collapse
|
31
|
Kristensen GB, Vergote I, Stuart G, Del Campo JM, Kaern J, Lopez AB, Eisenhauer E, Aavall-Lundquist E, Ridderheim M, Havsteen H, Mirza MR, Scheistroen M, Vrdoljak E. First-line treatment of ovarian cancer FIGO stages IIb–IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer 2003. [DOI: 10.1136/ijgc-00009577-200311001-00008] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
The objective of this study was to compare the safety and efficacy of carboplatin plus epirubicin and paclitaxel (TEC) to carboplatin and paclitaxel (TC), in the treatment of epithelial ovarian, peritoneal, or tubal carcinoma. Between March 1999 and August 2001, 887 patients were randomized to receive six to nine cycles of paclitaxel (175 mg/m2, 3 h intravenously) followed by carboplatin (AUC 5, Calvert formula) with or without epirubicin (75 mg/m2 intravenously prior to paclitaxel), on a 3-weekly schedule. The primary endpoint was progression-free survival. Demographic information: Residual disease <1 cm was reported on 41% of patients. At the end of treatment, 65% in the TEC and 55% in the TC arm had achieved a clinical complete response, and 18 and 25% a clinical partial response resulting in an overall response rate of 83% in the TEC and 80% in the TC arm, whereas 7 and 9% had progressive disease, respectively. The three-drug combination produced a markedly higher myelotoxicity, resulting in a higher frequency of febrile neutropenia (12.5% of the TEC and 1.5% of the TC patients) and a higher number of dose reductions and treatment delays. Cycle prolongation above seven days was seen in 7 and 5% of cycles in the TEC and TC arm, respectively. Stomatitis ≥ grade 3 was also higher with TEC (4% TEC and 0.5% TC). Reductions in left ventricular ejection fraction of more than 15% after six courses were slightly more common with the TEC regimen (3% versus 1.5%), but the difference was not statistically significant (P = 0.2). In conclusion, treatment with the TEC combination produced a higher rate of complete responses than treatment with the TC combination. Toxicity was manageable. Long-term survival data are awaited.
Collapse
|
32
|
Vrdoljak E, Hamm W. Current state-of-the-art of concomitant chemoradiation in cervical carcinomas. EUR J GYNAECOL ONCOL 2003; 24:475-9. [PMID: 14658585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
Despite screening programs, cervical carcinoma remains a major health problem throughout the world. Until recently pelvic radiation has been the standard therapy for advanced disease with overall five-year survival rates of 50%. Recently, five randomized trials demonstrated a significant survival advantage for the concomitant administration of radiotherapy and cisplatin-based chemotherapy. Although the trials vary somewhat in terms of stage of disease, dose of radiation, and schedule of radiation and cisplatin, they all demonstrated a significant survival benefit for the combined approach. Congruent to these findings are results from a meta-analysis based on the data from 19 trials with 4,580 randomized patients. The absolute increase in progression-free and overall survival was 16% and 12%, respectively. Contrary to these findings is the result of the National Cancer Institute of Canada (NCCI) trial. Despite that result cisplatin-based concomitant chemoradiotherapy has become the standard treatment of locally advanced cervical cancer.
Collapse
Affiliation(s)
- E Vrdoljak
- Center of Oncology, University of Split School of Medicine, Clinical Hospital of Split, Croatia
| | | |
Collapse
|
33
|
Phan TP, Crane CH, Janjan NA, Vrdoljak E, Milas L, Mason KA. WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment. Int J Pancreatol 2002; 29:19-23. [PMID: 11558629 DOI: 10.1385/ijgc:29:1:19] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND The nucleoside analog gemcitabine is a potent radiosensitizer of both tumor and normal mucosa, so severe toxic reactions have resulted from its combination with radiation in some clinical treatment schedules for pancreatic cancer. WR-2721 (amifostine) has been shown to reduce normal tissue toxicity produced from both radiation treatment and some chemotherapeutics. The aim of this study was to determine if WR-2721 can protect the gastrointestinal mucosa from injury by concurrent gemcitabine and radiation treatment. METHODS AND MATERIALS Gemcitabine was injected ip into C3Hf/Kam mice at a concentration of 33 mg/kg 24 h before whole-body irradiation. A single dose (200 mg/kg) of WR-2721 was given 30 min before the radiation treatment or 30 min before gemcitabine or at both times. A quantitative assessment of the chemotherapy/radiation-induced damage was carried out using the mouse microcolony assay for stem cell survival in the intestinal crypts. RESULTS WR-2721 given 30 min before gemcitabine followed 24 h later by radiation did not confer any protection to the jejunum (DMF 0.95). However, WR-2721 administered 30 min before radiation without or with prior gemcitabine produced protection factors (PF) of 1.35 and 1.42 CONCLUSIONS WR-2721 did not directly protect the gastrointestinal mucosa from gemcitabine toxicity, but it did protect the gemcitabine-radiosensitized mucosa from acute radiation damage by a factor of 1.42. Therefore, in clinical treatment protocols using concurrent chemoradiation with gemcitabine, WR-2721 may have clinical utility in protecting against radiation-induced mucosal toxicity.
Collapse
Affiliation(s)
- T P Phan
- Department of Experimental Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030-4095, USA
| | | | | | | | | | | |
Collapse
|
34
|
Vrdoljak E, Mise K, Sapunar D, Rozga A, Marusic M. Staging in untreated patients with small cell lung cancer. Neoplasma 2001; 48:154-6. [PMID: 11478698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
In order to describe the real biological behavior of the small-cell lung cancer we have analyzed survival rates of 66 patients with small-cell lung cancer who did not receive any specific anti cancer therapy. Also, objective of this study was to evaluate the staging system of the small-cell lung cancer. Untreated small-cell lung cancer patients with limited stage disease had statistically significant (p < 0.05) better survival rates in comparison to patients with extensive stage disease. T and N factor of the TNM classification did not influence the survival in untreated small-cell lung cancer patients. It appears that the TNM staging system is not predicting survival probabilities of untreated patients with small-cell lung cancer, while the two-stage system appeared very well based on survival probabilities of these patients.
Collapse
Affiliation(s)
- E Vrdoljak
- Center of Oncology, Clinical Hospital Split, Croatia.
| | | | | | | | | |
Collapse
|
35
|
Krolo M, Vilović K, Sapunar D, Vrdoljak E, Saraga-Babic M. Fibronectin expression in the developing human spinal cord, nerves, and ganglia. Croat Med J 1998; 39:386-91. [PMID: 9841937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023] Open
Abstract
AIM Analysis of developmental role of fibronectin during differentiation of the human spinal cord, nerves, and ganglia. METHODS Seven normal human embryos and fetuses between the 7th and 9th developmental week and a 9-week fetus with cervical spina bifida were histologically examined on hematoxylin and eosin stained serial paraffin sections of thoracic axial segments. Monoclonal antibody to the human cell fibronectin fragment was used for immunohistochemical detection of fibronectin. RESULTS In the 7th and 8th week of development, fibronectin was weakly expressed in the ventricular and intermediate zones of the spinal cord. Intense fibrillar expression was found in the marginal zone of the spinal cord - first over the ventral gray horns and later over the lateral and dorsal gray horns, and along the pathways of ventral and dorsal roots of the spinal nerves and in the spinal ganglia. At 9th week, fibronectin expression disappeared in the ventricular and intermediate zones a nd became weak and granular in the marginal zone of the spinal cord. In the spinal cord of a 9-week malformed fetus with cervical spina bifida, fibronectin expression was completely absent. Fibronectin was expressed in the nerves and ganglia throughout the investigated period, both in normal and malformed human conceptuses. CONCLUSION Transient expression of fibronectin in the human spinal cord coincided with the most intense neuronal differentiation. Temporal and spatial expression of fibronectin during normal development, and its absence in a malformed human fetus suggests developmental role of fibronectin for the normal formation of the spinal cord.
Collapse
Affiliation(s)
- M Krolo
- Department of Histology and Embryology, Split University School of Medicine, Spinciceva 1, HR-21000 Split, Croatia
| | | | | | | | | |
Collapse
|
36
|
Sapunar D, Vilovic K, Pintaric I, Vrdoljak E, Petri N, Saraga-Babic M. Effect of maternal hyperoxygenation on experimentally produced uteroplacental insufficiency in the rat. Reprod Fertil Dev 1996; 8:379-81. [PMID: 8795100 DOI: 10.1071/rd9960379] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
The paper examines the effects of maternal hyperoxygenation on uteroplacental insufficiency produced by ligation of the uterine artery. Maternal hyperoxygenation did not significantly affect experimentally produced growth retardation or survival of the fetuses from the ligated horn. Analysis of the vascular anatomy revealed that additional oxygen improves the survival of fetuses compromised by uteroplacental insufficiency only in the presence of anastomosis between the uterine and ovarian arteries. The study demonstrated the importance of that anastomosis in evaluating the results obtained by this experimental model.
Collapse
Affiliation(s)
- D Sapunar
- Department of Histology and Embryology, University of Zagreb Medical School, KBC Firule, PAK, Split, Republic of Croatia
| | | | | | | | | | | |
Collapse
|
37
|
Abstract
The survival rate analysis of 130 patients with non-small-cell lung cancer who did not receive any specific anticancer therapy showed no statistically significant differences in the survival rates between various TNM combinations classified into stage groups II, IIIa, IIIb, and IV, as proposed by Mountain in 1989 and adopted by the American Joint Committee on Cancer. Following these findings, based on survival probabilities, two distinctive staging groups could be distinguished. The first stage group was composed of only the T1, 2N0, M0 combination, and the second of all other TNM combinations. In a purely biologic sense of tumor growth, the lymph node involvement appeared to be the crucial factor determining the length of survival.
Collapse
|
38
|
Vrdoljak E, Borchardt PE, Bill CA, Stephens LC, Tofilon PJ. Influence of X-rays on early response gene expression in rat astrocytes and brain tumour cell lines. Int J Radiat Biol 1994; 66:739-46. [PMID: 7814972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The effects of ionizing radiation on c-fos, c-jun and jun-B mRNA levels were determined in cultures of rat perinatal type 1 astrocytes and two rat brain tumour cell lines, 175A and 9L. In astrocyte cultures X-ray doses as low as 1 Gy induced the expression of c-fos and jun-B but had essentially no effect on c-jun. The maximum increase in expression was found 1 h after irradiation, which then rapidly returned to control levels. These findings suggest that astrocytes may play a role in mediating the radiation response of the central nervous system via X-ray-induced changes in gene expression. In contrast, doses of up to 20 Gy had no effect on c-fos, c-jun and jun-B mRNA levels in the two brain tumour cell lines. In addition, whereas 12-O-tetradecanoylphorbol-13-acetate induced the expression of these genes in astrocytes, it had little or no effect on fos or jun expression in 9L or 175A cells. These results suggest that the signal transduction pathways mediating radiation-induced gene expression may be different in normal astrocytes and brain tumour cells.
Collapse
Affiliation(s)
- E Vrdoljak
- Department of Experimental Radiotherapy, University of Texas M.D. Anderson Cancer Center, Houston 77030
| | | | | | | | | |
Collapse
|
39
|
Cvitanović S, Marusić M, Juricić M, Vrdoljak E, Petrovecki M, Rozga A, Stavljenić-Rukavina A. Hypersensitivity to Parietaria officinalis pollen in newcomers to the area with the plant. Allergy 1993; 48:592-7. [PMID: 8116858 DOI: 10.1111/j.1398-9995.1993.tb00754.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Hypersensitivity to Parietaria officinalis (wall pellitory) pollen and other environmental allergens was studied in pollinosis patients allergic to P. officinalis pollen who were born in areas without P. officinalis and later moved to the city of Split, where P. officinalis is responsible for some 65% of pollinosis cases. Highly significant positive correlations were found for both the intensity of skin test reaction and concentration of specific serum IgE with the length of residence in the area. In contrast, the respective data on subjects hypersensitive to P. officinalis pollen allergen, but born and living in the area of Split, revealed a tendency to negative correlation between age and intensity of hypersensitivity to P. officinalis. A number of patients from both groups were tested for presence of serum IgE antibodies specific for 14 common environmental allergens. Hypersensitivity to P. officinalis pollen was associated with hypersensitivity to olive, mugwort, and birch pollen in newcomers; hypersensitivity to birch and, to some extent, olive pollen was significantly more frequent in newcomers than in autochthonous patients who were allergic to P. officinalis pollen. Regardless of whether the patients were autochthons or newcomers to the area with P. officinalis, hypersensitivity to P. officinalis mostly excluded hypersensitivity to Dermatophagoides farinae and D. pteronyssinus, and vice versa.
Collapse
Affiliation(s)
- S Cvitanović
- Department of Clinical Laboratory-Diagnosis, Zagreb University School of Medicine, Croatia
| | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
Aclacinomycin A (ACM), a potent inducer of leukemic cell differentiation, significantly enhances the radiosensitivity of a human colon tumor cell line (Clone A) when cultures are exposed to 15-nM concentrations for 3 days before irradiation. We now demonstrate that incubation with ACM after irradiation can also enhance Clone A cell killing. The maximum increase in cell killing, based on colony-forming ability, occurred when Clone A cells were exposed for 1 h to 5 microM ACM added 1 or 2 h after irradiation. The post-irradiation ACM protocol reduced the terminal slope (as reflected by D0) of the radiation cell survival curve with no change in the low-dose, shoulder region of the curve (Dq value). In contrast, for pre-irradiation treatment with ACM (15 nM, 3 days), the shoulder region of the curve was reduced with no change in the terminal slope. For pre- and post-irradiation ACM treatment the dose enhancement factors at 0.10 survival were 1.22 and 1.28, respectively. When ACM was given both before and after irradiation both the shoulder and terminal slope values decreased to produce a dose enhancement factor at a surviving fraction of 0.10 of 1.50. These data suggest that the enhanced cell killing produced by pre- and post-irradiation treatment with ACM is achieved through different mechanisms.
Collapse
Affiliation(s)
- C A Bill
- Department of Experimental Radiotherapy, University of Texas M.D. Anderson Cancer Center, Houston 77030
| | | | | | | |
Collapse
|
41
|
Bill CA, Grochan BM, Vrdoljak E, Mendoza EA, Tofilon PJ. Decreased repair of radiation-induced DNA double-strand breaks with cellular differentiation. Radiat Res 1992; 132:254-8. [PMID: 1438708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Although the majority of mammalian cells in situ are terminally differentiated, most DNA repair studies have used proliferating cells. In an attempt to understand better the relationship between differentiation and DNA repair, we have used the murine 3T3-T proadipocyte cell line. In this model system, proliferating (stem) cells undergo growth arrest (GD cells) and subsequently terminally differentiate into adipocytes when exposed to media containing platelet-depleted human plasma. Pulsed-field gel electrophoresis was used to evaluate the induction and repair of DNA double-strand breaks (DSBs) after ionizing radiation. The levels of radiation-induced DSBs in GD and terminally differentiated cells were similar, but in both cases greater than those found in stem cells at each radiation dose tested (0 to 40 Gy); these differences appear to be due to growth arrest in G1 phase. DNA DSBs were repaired with biphasic kinetics for each cell type. For terminally differentiated cells 25% of DNA DSBs remained unrejoined compared with < 10% for GD and stem cells after a repair time of 4 h. These data indicate that terminal differentiation of 3T3-T cells is associated with a reduction in the repair of ionizing radiation-induced DNA DSBs.
Collapse
Affiliation(s)
- C A Bill
- Department of Experimental Radiotherapy, University of Texas M. D. Anderson Cancer Center, Houston 77030
| | | | | | | | | |
Collapse
|
42
|
Cvitanović S, Grbić D, Zekan L, Boban M, Vrdoljak E, Parpura V, Petrović S, Marusić M. Hypersensitivity to P. officinalis pollen: correlation of IgE with skin testing methods. Allergol Immunopathol (Madr) 1989; 17:197-200. [PMID: 2816661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Fifty pollinosis patients, who have reported contact with P. officinalis, were tested for skin sensitivity with P. officinalis pollen extract. Intracutaneous testing and the skin prick method were employed and their sensitivity verified with regard to serum concentrations of specific IgE antibodies determined with the RAST method. Two criteria of the skin prick method evaluation were employed. The intracutaneous method correlated best with RAST. In contrast to intracutaneous testing, the skin prick method did not produce any false-positive results; however, due to a few false-negative cases observed, it appeared that in borderline-negative cases the skin prick method would require determination of serum IgE antibodies to reach a clear-cut diagnosis.
Collapse
Affiliation(s)
- S Cvitanović
- Department of Pulmonary Diseases, Clinical Center Firule, Croatia, Yugoslavia
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Cvitanović S, Grbić D, Zekan L, Petrović S, Vrdoljak E, Parpura V, Boban M. [Ketotifen and nasal steroids in the therapy of pollinosis]. Plucne Bolesti 1989; 41:205-8. [PMID: 2636408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Thirty-five patients with seasonal pollen rhinitis due to hypersensitivity to Parietaria officinalis pollen were randomized and treated with ketotifen and with a combination of ketotifen and beclomethason diproprionate, a nasal steroid. The study was timed to cover the Parietaria off. pollination period (4 months), which was documented by the determination of air concentration of the pollen. Respiratory symptoms and additional medications were scored according to a defined control. During the peak pollen period, both groups suffered from intensified pollinosis symptoms which prompted additional medication. The increases, however, were less significant in the group treated with the combination of the two drugs, i.e. better results were obtained with the ketotifen-beclomethasone diproprionate combination than with ketotifen alone.
Collapse
|